Cytosorbents Corp
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
CTSO$5.80-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
STOCKHOLDERS’ EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2023, 2022 and 2021
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · · · · · · · · · Accumulated · · · · · · | |||||||||||||||||
| · · · · · · · Additional · · Other · · · · · · | |||||||||||||||||
| · · Common Stock · · Paid-In · · Comprehensive · · Accumulated · · Stockholders’ | |||||||||||||||||
| · Shares · Par value · Capital · Income (Loss) · Deficit · Equity | |||||||||||||||||
| | | | | | | | | | | | | | | | | | |
| Balance at December 31, 2020 | 43,221,999 | | $43,222 | | $277,533,082 | | $(1,734,078) | | $(196,626,647) | | $79,215,579 | ||||||
| Stock-based compensation - employees, consultants and directors | — | | — | | 4,020,819 | | — | | — | | 4,020,819 | ||||||
| Issuance of common stock - offerings, net of fees incurred | — | | — | | (90,000) | | — | | — | | (90,000) | ||||||
| Issuance of restricted stock options | | 106,662 | | | 107 | | | 928,310 | | | — | | | — | | | 928,417 |
| Proceeds from exercise of stock options | 139,102 | | 139 | | 805,060 | | — | | — | | 805,199 | ||||||
| Cashless exercise of stock options | | 10,724 | | 10 | | (2,842) | | — | | — | | (2,832) | |||||
| Other comprehensive income, foreign currency translation adjustment | — | | — | | — | | 2,259,663 | | — | | 2,259,663 | ||||||
| Net loss | — | | — | | — | | — | | (24,558,648) | | (24,558,648) | ||||||
| Balance at December 31, 2021 | 43,478,487 | | 43,478 | | 283,194,429 | | 525,585 | | (221,185,295) | | 62,578,197 | ||||||
| Stock-based compensation - employees, consultants and directors | — | | — | | 3,423,517 | | — | | — | | 3,423,517 | ||||||
| Legal/audit fees related to ATM offering | — | | — | | (40,358) | | — | | — | | (40,358) | ||||||
| Issuance of restricted stock options | | 144,728 | | | 145 | | | 379,946 | | | — | | | — | | | 380,091 |
| Other comprehensive loss, foreign currency translation adjustment | — | | — | | — | | 1,803,610 | | — | | 1,803,610 | ||||||
| Stock issued to vendor in lieu of cash payment | 12,500 | | 12 | | 42,487 | | — | | — | | 42,499 | ||||||
| Net loss | — | | — | | — | | — | | (32,812,583) | | (32,812,583) | ||||||
| Balance at December 31, 2022 | 43,635,715 | | 43,635 | | 287,000,021 | | 2,329,195 | | (253,997,878) | | 35,374,973 | ||||||
| Stock-based compensation - employees, consultants and directors | — | | — | | 3,329,307 | | — | | — | | 3,329,307 | ||||||
| Proceeds from the exercise of stock options for cash | 84,905 | | 85 | | 218,193 | | — | | — | | 218,278 | ||||||
| Issuance of common stock offerings, net of fees incurred | 10,389,554 | | 10,390 | | 14,245,544 | | — | | — | | 14,255,934 | ||||||
| Issuance of restricted stock options | 130,091 | | 130 | | 403,809 | | — | | — | | 403,939 | ||||||
| Other comprehensive loss, foreign currency translation adjustment | — | | — | | — | | (1,799,874) | | — | | (1,799,874) | ||||||
| Net loss | — | | — | | — | | — | | (28,507,394) | | (28,507,394) | ||||||
| Balance at December 31, 2023 | 54,240,265 | | $54,240 | | $305,196,874 | | $529,321 | | $(282,505,272) | | $23,275,163 | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.